Association for high BMI and colorectal cancer risk most pronounced using BMI at least eight years before diagnosis.
Adding bevacizumab to treatment with trifluridine-tipiracil improves outcomes in patients with refractory, metastatic colorectal cancer, a phase 3 study suggests.